Physician
Karimi, Afsoon
Karimi, Afsoon was paid $7.28M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 23% of everything it billed.
33Billing provider infoKARIMI, AFSOON
DARIEN, IL 60561
DARIEN, IL 60561
33aNPI1144299256assigned 03/14/2006
33bProvider typePediatrics Physician
28Total paid$7.28M
24GClaims247,053
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#4 of 1,805
Median peer was paid$55K
This provider vs. median132×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,979 | $742K | |
| 2019 | 38,127 | $966K | |
| 2020 | 30,932 | $757K | |
| 2021 | 33,901 | $895K | |
| 2022 | 38,524 | $1.28M | |
| 2023 | 37,925 | $1.47M | |
| 2024incomplete | 37,665 | $1.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 22,061 | 17,632 | $1.66M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 29,435 | 21,854 | $1.41M |
| 95144 | 11% | 6,639 | 764 | $805K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.1% | 5,553 | 4,129 | $441K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.6% | 4,661 | 3,545 | $337K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 14,816 | 11,745 | $231K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.9% | 2,930 | 1,945 | $210K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.5% | 14,450 | 13,019 | $180K |
| 96127 | 2.3% | 11,509 | 8,693 | $165K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.6% | 2,841 | 2,058 | $116K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.3% | 1,497 | 1,053 | $97K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 4,737 | 2,741 | $95K |
85 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 2,554 | $90K |
| 96136 | 1.2% | 2,448 | $84K | |
| 90651 | 1.1% | 2,963 | $78K | |
| 99204 | Doctor's office visit, new patient (more involved) | 1.0% | 932 | $74K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,539 | $72K |
| 99173 | <1% | 9,569 | $70K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 617 | $59K |
| 93000 | <1% | 2,586 | $54K | |
| 90620 | <1% | 2,616 | $53K | |
| 99384 | <1% | 536 | $53K | |
| 99383 | <1% | 562 | $49K | |
| 90734 | <1% | 2,559 | $48K | |
| 83655 | <1% | 4,114 | $48K | |
| 86580 | <1% | 8,164 | $41K | |
| 90686 | <1% | 3,885 | $40K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 613 | $34K |
| 90670 | <1% | 1,682 | $31K | |
| 0071A | <1% | 701 | $29K | |
| 90744 | <1% | 2,885 | $29K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 343 | $27K |
| 90633 | <1% | 2,556 | $26K | |
| 90715 | <1% | 1,833 | $24K | |
| 0072A | <1% | 572 | $24K | |
| 36416 | <1% | 6,162 | $24K | |
| 0001A | <1% | 502 | $21K | |
| 90710 | <1% | 1,400 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,458 | $20K |
| 90649 | <1% | 953 | $20K | |
| 0002A | <1% | 417 | $18K | |
| 90619 | <1% | 989 | $17K | |
| 81025 | <1% | 3,581 | $15K | |
| 0124A | <1% | 360 | $15K | |
| 81003 | <1% | 5,876 | $13K | |
| 82962 | <1% | 6,745 | $13K | |
| 99385 | <1% | 114 | $12K | |
| 0004A | <1% | 292 | $12K | |
| 69209 | <1% | 1,381 | $12K | |
| 85018 | <1% | 4,902 | $11K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 249 | $11K |
| 90688 | <1% | 1,252 | $10K | |
| 81002 | <1% | 3,853 | $10K | |
| 90756 | <1% | 501 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 351 | $9K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 6,749 | $8K |
| 85014 | <1% | 3,258 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 150 | $6K |
| 94760 | <1% | 1,510 | $6K | |
| 90698 | <1% | 595 | $6K | |
| 90696 | <1% | 524 | $5K | |
| 0154A | <1% | 115 | $5K | |
| D1206 | Topical application of fluoride varnish | <1% | 183 | $5K |
| 0073A | <1% | 108 | $5K | |
| 82947 | <1% | 1,139 | $4K | |
| 90700 | <1% | 413 | $4K | |
| 90716 | <1% | 275 | $3K | |
| 80305 | <1% | 363 | $3K | |
| 90713 | <1% | 246 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 298 | $3K |
| 90677 | <1% | 69 | $3K | |
| 90680 | <1% | 335 | $3K | |
| 91320 | <1% | 63 | $3K | |
| 90461 | <1% | 3,034 | $3K | |
| 90707 | <1% | 200 | $3K | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 1,119 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 53 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 25 | $2K |
| 95117 | <1% | 216 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 33 | $2K |
| 99382 | <1% | 18 | $2K | |
| 0081A | <1% | 37 | $2K | |
| 90648 | <1% | 190 | $1K | |
| 99406 | <1% | 181 | $920.32 | |
| 87634 | <1% | 13 | $676.00 | |
| 90697 | <1% | 23 | $346.98 | |
| 90656 | <1% | 20 | $342.06 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,377 | $148.76 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 321 | $133.90 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 13 | $25.45 |
| 99072 | <1% | 364 | $20.00 | |
| 91307 | <1% | 559 | $1.06 | |
| 91300 | <1% | 430 | $0.98 | |
| 91312 | <1% | 73 | $0.14 | |
| 91308 | <1% | 16 | $0.04 | |
| 94664 | 0% | 16 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.